clinical trial · NCT00780910
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Chronic Hepatitis CMP-424RibavirinPeginterferon Alfa-2b
brief summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
started
Nov 1, 2008
primary completion
Oct 1, 2010
completion
Oct 1, 2010
last updated
Jan 6, 2026
official title
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol